Standard BioTools Inc. reported a total revenue of $85.3 million for the fiscal year ending December 31, 2025, a decline of 6% compared to $91.0 million in 2024. The decrease was primarily attributed to a $4.3 million drop in consumables revenue, which the company linked to macroeconomic pressures affecting customer spending. Additionally, service revenue fell by $1.9 million due to improved instrument reliability and changes in customer maintenance schedules. The company's gross profit for the year was $42.5 million, resulting in a gross margin of 50%, slightly up from 49% in the previous year.
In terms of operational changes, Standard BioTools underwent significant restructuring, including a reduction in workforce that impacted approximately 20% of its global staff. This move was part of a strategy to consolidate research and development capabilities into its Singapore facility, which is co-located with manufacturing operations. The company also completed a divestiture of its SomaScan Business to Illumina, which closed on January 30, 2026, for a total cash consideration of up to $425 million. This transaction is expected to provide additional financial flexibility and potential future revenue through earnout payments based on performance metrics.
The company’s total operating expenses for 2025 were $152.8 million, a decrease from $172.4 million in 2024. Research and development expenses fell by 10% to $26.0 million, reflecting a deferral of long-term projects. However, selling, general, and administrative expenses increased by 7% to $109.9 million, driven by higher personnel costs and stock-based compensation. The net loss from continuing operations was $58.8 million, compared to a loss of $90.9 million in the previous year.
Standard BioTools reported that as of December 31, 2025, it had cash, cash equivalents, and short-term investments totaling $187.6 million, down from $292.9 million in 2024. The company’s accumulated deficit reached $1.3 billion, highlighting ongoing financial challenges despite efforts to streamline operations and reduce costs. Looking ahead, Standard BioTools aims to leverage its retained mass cytometry and microfluidics businesses while focusing on expanding its customer base and enhancing product offerings to drive future growth.
About STANDARD BIOTOOLS INC.
Standard BioTools Inc. develops and commercializes advanced life science tools in proteomics and genomics, including instruments, consumables, and services for biomedical research, drug discovery, and clinical applications. Its platforms—SomaScan, CyTOF, Hyperion, and Biomark—enable high-throughput, precise molecular analysis across diverse therapeutic areas. The company serves research institutions, biopharma, and clinical labs worldwide, leveraging proprietary technologies and strategic acquisitions to accelerate biological insights and health innovations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.